Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830999 | 0.85 | PTGS2 (0.52) | PTGS2MEN1KMT2APIK3CALMNA | |
| SCHEMBL19953198 | 0.84 | PTGS2 (0.68) | PTGS2MEN1KMT2AATMPIK3CA | |
| SCHEMBL1075370 | 0.82 | PTGS2 (0.67) | PTGS2MEN1KMT2AATMPIK3CA | |
| SCHEMBL8800251 | 0.79 | PTGS2 (0.74) | PTGS2 | |
| Hydrochloric Acid SCHEMBL15953386 | 0.70 | CYP1A2 (0.41) | MEN1KMT2ALMNAUSP2MAPK1 | |
| SCHEMBL6510547 | 0.70 | PTGS2 (0.39) | PTGS2PIK3CAMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL2107151 | 0.70 | USP2 (0.64) | MEN1KMT2ALMNATP53USP2 | |
| SCHEMBL6294278 | 0.70 | PTGS2 (0.64) | PTGS2 | |
| SCHEMBL19953122 | 0.69 | HSP90AA1 (0.46) | MEN1KMT2AATMLMNATP53 | |
| SCHEMBL19953204 | 0.68 | PTGS2 (0.49) | PTGS2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1722784-A4 | ION CHANNEL MODULATORS | WYETH CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1722783-A4 | ION CHANNEL MODULATORS | WYETH CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7547717-B2 | Ion channel modulators | WYETH (US) | 2009-06-16 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| CN-1946397-A | Ion channel modulators | SCION PHARMACEUTICALS INC (US) | 2007-04-11 | — | — | CN | disclosed |
| CN-1938020-A | Ion channel modulators | SCION PHARMACEUTICALS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| CN-1930132-A | Ion channel modulators | WYETH CORP (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1722784-A2 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1722783-A2 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723117-A2 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005086895-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005086892-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005086836-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203159-A1 | Ion channel modulators | SCION PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | PTGS2 1158/4885MEN1 3147/4885KMT2A 3236/4885 |
| US-20050203159-A1 | Ion channel modulators | CACNA1B, CACNA1C, TRPV1 | PTGS2 1158/4885MEN1 3147/4885KMT2A 3236/4885 |
| US-20080090891-A1 | ION CHANNEL MODULATORS | CACNA1B, CACNA1C, TRPV1 | PTGS2 1158/4885MEN1 3147/4885KMT2A 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.